Thakore J H, Berti C, Dinan T G
Department of Psychological Medicine, St Bartholomew's Hospital, London, UK.
Acta Psychiatr Scand. 1996 Sep;94(3):194-7. doi: 10.1111/j.1600-0447.1996.tb09848.x.
While the positive symptoms of schizophrenia are amenable to treatment with standard neuroleptics, negative symptoms are often difficult to treat. Co-prescribing antidepressants, such as sertraline, for patients on stable neuroleptic depot preparations is one pharmacological method of overcoming this problem. A total of 20 patients with chronic schizophrenia were enrolled in an open trial over a 12-week period during which sertraline was added to their usual antipsychotic medication. Prior to this, baseline scores for positive and negative symptoms, and extrapyramidal side-effects, were measured. The addition of sertraline resulted in global improvement, with a significant reduction in positive and negative symptom scores and no increase in undesirable neuroleptic side-effects. Sertraline may act by indirectly reducing dopaminergic activity.
虽然精神分裂症的阳性症状可用标准抗精神病药物治疗，但阴性症状往往难以治疗。对于使用稳定长效抗精神病药物制剂的患者联合开具抗抑郁药（如舍曲林）是克服这一问题的一种药理学方法。共有20例慢性精神分裂症患者参加了一项为期12周的开放试验，在此期间，在其常规抗精神病药物治疗基础上加用舍曲林。在此之前，测量了阳性和阴性症状以及锥体外系副作用的基线评分。加用舍曲林后整体症状改善，阳性和阴性症状评分显著降低，且未增加抗精神病药物的不良副作用。舍曲林可能通过间接降低多巴胺能活性发挥作用。
